Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. - Wikidata - awgldk - TriplyDB

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

http://www.wikidata.org/entity/Q37416925

about

Translating the epitranscriptome Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications RNA-Based Vaccines in Cancer Immunotherapy The Epitranscriptome and Innate Immunity Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond Engine out of the chassis: cell-free protein synthesis and its uses N6-methyl-adenosine modification in messenger and long non-coding RNA The oral and craniofacial relevance of chemically modified RNA therapeutics Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation.Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis.Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA mRNA vaccine delivery using lipid nanoparticles.The notorious R.N.A. in the spotlight - drug or target for the treatment of disease Chemical and structural effects of base modifications in messenger RNA.Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications.Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation.Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.The dynamic epitranscriptome: N6-methyladenosine and gene expression control In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle.Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART Transcriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae.Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA.mRNA leapfrogs DNA to show promise for therapeutic gene transfer A Recombinant Collagen-mRNA Platform for Controllable Protein Synthesis Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression.Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK.Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo.Pseudouridine: still mysterious, but never a fake (uridine)!Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases.Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.Developing mRNA-vaccine technologies.

P2860

Q26747114-37BCD127-7AF8-4FCF-B8B6-16B9634F0B6B Q26772309-21DF5DE8-0EE3-46F3-86D3-1D47394C78AA Q26776028-B32516B4-5038-42AF-8623-83EFB7F5D2E9 Q26776423-94F4954F-B8F6-4EEF-917A-A20C9A2FFC6B Q26861563-CCC4ADC6-E1D7-40FB-9235-361D831A5DD8 Q26994662-56F41D46-5474-44AD-8CAB-8274DD23FFEB Q27022522-2CAAC8F5-FB26-48D2-8560-6DD3D31863D4 Q28072338-1785AAA7-08C7-4639-9E80-FA22BB3E3EFB Q28131663-330FC480-6D29-422C-A5DA-42DA41D958D4 Q28656365-D3DF4488-67D1-415B-BBEC-6E5D2637A401 Q30402786-74562F2E-AFB1-4E17-8954-B73C0D33265C Q30548207-6A0C48BE-F5E5-4B2A-BCCA-AD041A684540 Q30580723-B95C1C29-9AAA-4767-94EC-68251D6B2A2A Q30624869-9D69D27E-2EC4-4FB4-A8AB-727810C2FC29 Q30690412-0EAF71BA-49E7-4E25-B5B0-F9200D20D021 Q33652543-4B9F569A-D1AB-48B3-94B2-6E527D9C8AAB Q33711685-1B55BA16-980B-4342-AA8E-08843248A5E3 Q33739733-38FE4EB9-8706-4389-BDF4-FCB54586F38B Q33876249-43063527-AF3F-4533-BAE8-0730ECD4DE9A Q34055104-5203437C-B3FA-44B3-B1E2-36A91B6DF3DB Q34146278-B3DEE9DF-7B19-4F95-8BC7-584397AC6F04 Q34234240-94F0BAEF-4C1A-4B88-8597-6014D0D73CA6 Q34414288-02A1482D-BABF-4D71-AA52-4B2BED251143 Q34589906-91E0E653-DE84-4743-B26A-A96A402FD9F2 Q34647798-33CA6C38-99A0-4A5F-9164-E826DEC4CBDB Q35374452-881BAFED-ABC4-49D2-A276-C3A9A49A4753 Q35620847-F28ED573-7CC7-45CB-83FB-C08181F2BE2B Q35620919-D3372F97-5E6C-4BB5-94D2-28B958F1904E Q35677482-D97388A2-AA98-47B3-B23D-DFA4B7ED1B04 Q35876177-5BF205EF-D247-4EB0-90EF-B6CE9CE21305 Q35895269-1506AF6A-D65A-40A7-AD7F-EE690C72A9C4 Q35909697-F000DFD7-10E9-41E8-A7F7-027E6EECBC5B Q35936953-A4F749B9-23A0-4169-9291-5C9DA4F3FCFA Q35939486-F1415F8D-911C-4A87-B05E-58BA8A62687F Q35996243-86884121-A13F-46B6-ADB7-0806B5D09501 Q36190987-2B5FACEE-A202-4D2A-8274-A3BA237CD852 Q36216226-28D781FD-CC51-4248-BD9A-A67B17986F72 Q36218294-D34E6F30-9DD9-4923-8434-7A80D25FADC3 Q36673897-88A1FE04-0EE3-45AE-8A6F-98D5A730BB60 Q36684597-6F7B6DC0-BCA1-44D9-AF26-94D732516741

P2860

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

http://www.wikidata.org/entity/Q37416925

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Incorporation of pseudouridine ...... city and biological stability.

@en

Incorporation of pseudouridine ...... city and biological stability.

@nl

type

label

Incorporation of pseudouridine ...... city and biological stability.

@en

Incorporation of pseudouridine ...... city and biological stability.

@nl

prefLabel

Incorporation of pseudouridine ...... city and biological stability.

@en

Incorporation of pseudouridine ...... city and biological stability.

@nl

P1433

Q37416925-8741AEFC-9684-4597-907B-5CADCFF86B87

P1476

Q37416925-95A62B07-48C0-4182-84C1-DEE690874452

P2093

Q37416925-001F3A24-3CF5-4444-880A-1176A1B63F5C

Q37416925-0403CC05-B227-4AE0-B7D8-61DC797E6941

Q37416925-5A182D9F-5733-40B9-AD69-3F9680697137

Q37416925-7F3CF95A-643C-4975-BB24-2A8D48841963

Q37416925-9C366176-CDD5-4B43-85A0-C65AB4E00834

Q37416925-A3319B57-F39C-44A4-9104-10C0C9510396

Q37416925-C697D497-CD86-4509-850F-7A60BCD1E712

P2860

Q37416925-011CA368-5192-4D7E-B786-37363593E289

Q37416925-12224391-8727-440F-9201-C21C01B83984

Q37416925-1831774A-5110-46DF-B86A-5709E4FB8BC8

Q37416925-185D6631-3D07-423E-8B29-DCAA152BAC68

Q37416925-23D0A916-292B-4D1B-BB83-655566425E60

Q37416925-4BD1A561-D5DD-4031-B86F-A0616B9DD1B0

Q37416925-530C49C7-E3DA-4F23-B553-8CE8F1655E06

Q37416925-594D0C8A-01A1-4F81-8211-F4997EE05F05

Q37416925-5C3B09C7-9C51-4AAE-8EC4-C41966124EFA

Q37416925-6448BACD-D1F5-469B-8CBE-B7121E6A8F82

P304

Q37416925-D1AE359E-45A7-40C2-A81A-55243229CD69

P31

Q37416925-36171199-3E94-4644-BF8D-AB6662F5F8A7

P356

Q37416925-28205497-4BEE-4DDE-8CF6-BEB591C18974

P433

Q37416925-23E4F408-003D-4142-8276-BC5E5C0A715C

P478

Q37416925-6F04503E-8CAA-4290-97DA-6366EDEB6D46

P577

Q37416925-834ADEB7-A992-4251-96DB-97C39668804A

P5875

Q37416925-2B7A23F9-F2F1-43E2-8EC5-011FC3078E34

P698

Q37416925-59321B7B-4974-4EBD-A34B-6E4AC4E55D71

P932

Q37416925-37857625-14D9-41F0-84BA-D48A6E4897E0

P356

P1433

Molecular Therapy

P1476

Incorporation of pseudouridine ...... city and biological stability.

@en

P2093

Drew Weissman

http://www.w3.org/2001/XMLSchema#string

Frank A Welsh

http://www.w3.org/2001/XMLSchema#string

Hiroki Kato

http://www.w3.org/2001/XMLSchema#string

Hiromi Muramatsu

http://www.w3.org/2001/XMLSchema#string

János Ludwig

http://www.w3.org/2001/XMLSchema#string

Katalin Karikó

http://www.w3.org/2001/XMLSchema#string

Shizuo Akira

http://www.w3.org/2001/XMLSchema#string

P2860

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

5'-Triphosphate RNA is the ligand for RIG-I

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

Cell type-specific involvement of RIG-I in antiviral response

P304

1833-1840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2008.200

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23261139

http://www.w3.org/2001/XMLSchema#string

P698

18797453

http://www.w3.org/2001/XMLSchema#string

P932

2775451

http://www.w3.org/2001/XMLSchema#string